Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.

Saad, Fred; Clarke, Noel W; Oya, Mototsugu; Shore, Neal; Procopio, Giuseppe; Guedes, João Daniel; Arslan, Cagatay; Mehra, Niven; Parnis, Francis; Brown, Emma; Schlürmann, Friederike; Joung, Jae Young; Sugimoto, Mikio; Sartor, Oliver; Liu, Yu-Zhen; Poehlein, Christian; Barker, Laura; Del Rosario, Paula Michelle; Armstrong, Andrew J

Saad, Fred; Clarke, Noel W; Oya, Mototsugu; Shore, Neal; Procopio, Giuseppe; Guedes, João Daniel; Arslan, Cagatay; Mehra, Niven; Parnis, Francis; Brown, Emma; Schlürmann, Friederike; Joung, Jae Young; Sugimoto, Mikio; Sartor, Oliver; Liu, Yu-Zhen; Poehlein, Christian; Barker, Laura; Del Rosario, Paula Michelle; Armstrong, Andrew J.

Afiliação

Saad F; Centre Hospitalier de l'Université de Montréal, Montreal, Canada. Electronic address: fred.saad@umontreal.ca.
Clarke NW; The Christie and Salford Royal Hospital NHS Foundation Trusts and University of Manchester, Manchester, UK. Electronic address: noel.clarke@nca.nhs.uk.
Oya M; Keio University School of Medicine, Tokyo, Japan.
Shore N; Carolina Urologic Research Center, Myrtle Beach, SC, USA.
Procopio G; Programma Prostata Fondazione Istituto Nazionale Tumori Milano, Milan, Italy.
Guedes JD; Hospital de Base de São José do Rio Preto, São José do Rio Preto, Brazil.
Arslan C; Izmir Economy University Medical Point Hospital, Karsiyaka, Izmir, Turkey.
Mehra N; Radboud Universitair Medisch Centrum, Nijmegen, Netherlands.
Parnis F; Ashford Cancer Centre Research, Adelaide, Australia.
Brown E; University Hospital Southampton, Southampton, UK.
Schlürmann F; CHI de Cornouaille, Quimper, France.
Joung JY; National Cancer Center, Goyang, South Korea.
Sugimoto M; Kagawa University Hospital, Kagawa, Japan.
Sartor O; Mayo Clinic, Rochester, MN, USA.
Liu YZ; Precision Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
Poehlein C; Merck & Co, Rahway, NJ, USA.
Barker L; Global Medicines Development, Oncology R&D, AstraZeneca, Cambridge, UK.
Del Rosario PM; Global Medicines Development, Oncology R&D, AstraZeneca, Cambridge, UK.
Armstrong AJ; Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC, USA.

Lancet Oncol ; 24(10): 1094-1108, 2023 Oct.

Article em En | MEDLINE | ID: mdl-37714168

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google